Constellation raises $32 million in series A financing

Proceeds from the financing will be used to establish the discovery platform and accelerate the development of a preclinical candidate pipeline of epigenetic-targeted drugs.

The company’s initial focus is modulating epigenetic function, particularly histone modification, to discover and develop novel drugs for oncology. Constellation’s technology platform is also applicable to other therapeutic areas including autoimmune, inflammatory and neurological diseases.

Mark Levin, interim CEO, Constellation Pharmaceuticals, said: “Through Epigenetics, which represents a breakthrough in our understanding of biology at an entirely new level, at the interface between DNA and gene expression, we believe there is an unprecedented opportunity to create a novel class of drugs that will target gene function in a completely new and enhanced way.”